Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00433147 · ClinicalTrials.gov registry record · Phase 2
A Study of AT2101 (Afegostat Tartrate) in Adult Patients With Type 1 Gaucher Disease Currently Receiving Enzyme Replacement Therapy
A Phase 2 study of Gaucher Disease and Gaucher Disease, Type 1, sponsored by Amicus Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
- 10
- Study locations
NCT00433147 is a Phase 2 study of Gaucher Disease and Gaucher Disease, Type 1 that has completed, run by Amicus Therapeutics. The registered enrollment target is 30 participants, below the 1,056-participant average among 13 other Gaucher Disease trials with a reported enrollment target (97% lower). The trial reports 10 study locations across 9 states.
The verdict
NCT00433147, a Phase 2 study of Gaucher Disease and Gaucher Disease, Type 1, has completed, sponsored by Amicus Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
- 10
- Study locations
Study Summary
This study was conducted to test the safety and tolerability of afegostat tartrate in participants with type 1 Gaucher disease already receiving enzyme replacement therapy.
Conditions Studied
Interventions
- DRUG Afegostat tartrate
Study Locations (10)
Pennsylvania
- - Philadelphia
- - Pittsburgh
California
- - San Francisco
Florida
- - Coral Springs
Georgia
- - Decatur
Iowa
- - Iowa City
New York
- - New York
Ohio
- - Cincinnati
Oregon
- - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2007-03-23 |
| Est. Completion | 2008-02-19 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00433147
The ClinicalTrials.gov registry entry for NCT00433147 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,056-participant average among 13 other Gaucher Disease trials with a reported enrollment target (97% lower). The listed sponsor is Amicus Therapeutics, which has 34 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Gaucher Disease appearing as the primary indexed condition, and to 1 intervention - of which Afegostat tartrate is the first listed.
NCT00433147 reports 10 study locations spanning 9 distinct geographic areas - top geographies include Pennsylvania, California, Florida.
Frequently Asked Questions
What is clinical trial NCT00433147 about?
NCT00433147 is a clinical study titled "A Study of AT2101 (Afegostat Tartrate) in Adult Patients With Type 1 Gaucher Disease Currently Receiving Enzyme Replacement Therapy". This study was conducted to test the safety and tolerability of afegostat tartrate in participants with type 1 Gaucher disease already receiving enzyme replacement therapy.
What is the current status of trial NCT00433147?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2007-03-23. Estimated completion is 2008-02-19.
What conditions does trial NCT00433147 study?
This clinical trial studies the following conditions: Gaucher Disease, Gaucher Disease, Type 1, Type 1 Gaucher Disease.
What interventions are being tested in trial NCT00433147?
The interventions under investigation include: Afegostat tartrate (DRUG).
Who is sponsoring clinical trial NCT00433147?
This trial is sponsored by Amicus Therapeutics, which has 34 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00433147 being conducted?
This trial has 10 study locations across California, Florida, Georgia, Iowa, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Gaucher Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of GA-GCB Enzyme Replacement Therapy in Type 1 Gaucher Disease Patients Previously Treated With Imiglucerase
COMPLETED · Phase 2
-
A Study of Oral AT2101 (Afegostat Tartrate) in Treatment-naive Patients With Gaucher Disease
COMPLETED · Phase 2
-
Extracellular Vesicles as Potential Biomarkers and Therapeutic Target in Gaucher Disease
RECRUITING
-
A Long-term Follow-up Study of Gaucher Disease
RECRUITING
-
Gaucher Disease Outcome Survey (GOS)
RECRUITING
-
International Collaborative Gaucher Group (ICGG) Gaucher Disease Registry & Pregnancy Sub-registry
RECRUITING
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.